Trials / Completed
CompletedNCT03489421
Mitochondria in HIV and Aging (MITO+)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 14 (actual)
- Sponsor
- University of Colorado, Denver · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Older adults with human immunodeficiency virus (HIV) and a long history of antiretroviral therapy have more mitochondrial dysfunction- the cells that help them make energy. This dysfunction in mitochondria may lead to symptoms of muscle fatigue, physical function impairment, and impaired exercise tolerance compared to HIV-uninfected controls of a similar age and body mass index (BMI). Furthermore, the investigators hypothesize that the older antiretroviral therapy (ART) of tenofovir disoproxil fumarate (TDF) is associated with greater impairment in mitochondrial function than the newer agent, tenofovir alafenamide (TAF).
Conditions
Timeline
- Start date
- 2018-12-15
- Primary completion
- 2019-09-05
- Completion
- 2019-09-05
- First posted
- 2018-04-05
- Last updated
- 2019-09-26
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT03489421. Inclusion in this directory is not an endorsement.